BusinessEconomy

Supercharge Your Portfolio: Discover High-Yield Dividend Stocks Endorsed by Top Analysts

During times of market turbulence and uncertainty, many investors turn to dividend-yielding stocks. These are often companies with strong free cash flows that reward shareholders through generous dividend payouts. If you’re interested in the latest analyst takes on your preferred stocks, consider reviewing their ratings on the Analyst Stock Ratings page. This provides access to a comprehensive database of analyst ratings, including the ability to sort by accuracy. Take a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts.

Here are the ratings from the most accurate analysts for three high-yielding stocks in the health care sector:

AstraZeneca PLC (NASDAQ: AZN) Dividend Yield: 3.00%

  • Argus Research analyst Jasper Hellweg maintained a Buy rating and adjusted the price target from $85 to $80 on May 26, 2023. This analyst boasts a 66% accuracy rate.
  • SVB Leerink analyst Andrew Berens maintained an Outperform rating and raised the price target from $78 to $79 on Nov. 14, 2022. This analyst boasts a 55% accuracy rate. Recent News: AstraZeneca reported topline results from the TROPION-Lung01 phase 3 trial of datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer.

Medtronic plc (NYSE: MDT) Dividend Yield: 3.19%

  • Stifel analyst Rick Wise maintained a Buy rating and increased the price target from $90 to $92 on May 26, 2023. This analyst boasts an 80% accuracy rate.
  • Wells Fargo analyst Larry Biegelsen upgraded the stock from Equal-Weight to Overweight and raised the price target from $77 to $100 on April 24, 2023. This analyst boasts a 77% accuracy rate. Recent News: Medtronic presented new clinical and real-world data on the MiniMed 780G system at the 83rd American Diabetes Association Scientific Sessions.

CVS Health Corporation (NYSE: CVS) Dividend Yield: 3.49%

  • Mizuho analyst Ann Hynes maintained a Buy rating and adjusted the price target from $120 to $88 on July 11, 2023. This analyst boasts a 72% accuracy rate.
  • Truist Securities analyst David Macdonald maintained a Buy rating and adjusted the price target from $109 to $103 on June 20, 2023. This analyst boasts a 78% accuracy rate. Recent News: CVS Health recently entered into an 18-megawatt agreement with Constellation Energy Corporation to purchase zero-emission, renewable energy. This commitment will offset the annual electricity consumption of its 147 CVS Health locations throughout Michigan.

Kindly note that the information provided is based on the latest available data and prices.

Related Posts

1 of 66

Leave A Reply

Your email address will not be published. Required fields are marked *